dAurAB5 is a dual PROTAC degrader targeting Aurora-A (DC50= 8.8 nM) and Aurora-B (DC50= 6.1 nM). It induces the degradation of Aurora-A and Aurora-B, leading to reduced N-Myc levels and decreased viability of IMR32 neuroblastoma cells. Additionally, dAurAB5 downregulates the levels of AAK1, PTK2, GAK, and TTK. This compound is applicable in cancer research, including neuroblastoma.

Aurora A:8.8 nM (DC50)

dAurAB5, when administered at 500 nM for 24 hours, can significantly degrade Aurora-A and Aurora-B by 84% and 82% respectively. In IMR32 cells, dAurAB5 (500 nM, 24 hours) reduces N-Myc levels by 45%. At a concentration of 100 nM for 4 hours, it causes 83% degradation of Aurora-A and 95% degradation of Aurora-B in IMR32 cells. Furthermore, dAurAB5 at 200 nM for 6 hours decreases the abundance of Aurora-A, as well as AAK1, PTK2, GAK, and TTK in MYCN-amplified Kelly neuroblastoma cells, without affecting Aurora-B levels. dAurAB5, across a range of 0-1000 nM for 24 hours, reduces cell viability in IMR32 cells with minimal cytotoxicity on HEK293 cells.